Ceftolozane-tazobactam IV
ApprovedWithdrawn 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neutropenia, Febrile
Conditions
Neutropenia, Febrile, Hematologic Cancer
Trial Timeline
Aug 1, 2022 → Jun 1, 2024
NCT ID
NCT05061654About Ceftolozane-tazobactam IV
Ceftolozane-tazobactam IV is a approved stage product being developed by Merck for Neutropenia, Febrile. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05061654. Target conditions include Neutropenia, Febrile, Hematologic Cancer.
What happened to similar drugs?
7 of 17 similar drugs in Neutropenia, Febrile were approved
Approved (7) Terminated (4) Active (8)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05061654 | Approved | Withdrawn |
Competing Products
20 competing products in Neutropenia, Febrile